KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $1.5 million.

  • Adaptive Biotechnologies' Receivables - Other rose 1538.46% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 1538.46%. This contributed to the annual value of $1.3 million for FY2024, which is 3000.0% up from last year.
  • According to the latest figures from Q3 2025, Adaptive Biotechnologies' Receivables - Other is $1.5 million, which was up 1538.46% from $1.3 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Receivables - Other ranged from a high of $2.8 million in Q1 2021 and a low of $800000.0 during Q2 2022
  • Moreover, its 5-year median value for Receivables - Other was $1.2 million (2024), whereas its average is $1.3 million.
  • In the last 5 years, Adaptive Biotechnologies' Receivables - Other surged by 5555.56% in 2021 and then crashed by 6521.74% in 2022.
  • Adaptive Biotechnologies' Receivables - Other (Quarter) stood at $1.4 million in 2021, then plummeted by 42.86% to $800000.0 in 2022, then increased by 25.0% to $1.0 million in 2023, then increased by 30.0% to $1.3 million in 2024, then rose by 15.38% to $1.5 million in 2025.
  • Its Receivables - Other stands at $1.5 million for Q3 2025, versus $1.3 million for Q2 2025 and $1.5 million for Q1 2025.